BACKGROUND: The morbidity and mortality associated with opioid and benzodiazepine co-prescription is a pressing national concern. Little is known about patterns of opioid and benzodiazepine use in patients with acute low back pain or lower extremity pain. OBJECTIVE: To characterize patterns of opioid and benzodiazepine prescribing among opioid-naïve, newly diagnosed low back pain (LBP) or lower extremity pain (LEP) patients and to investigate the relationship between benzodiazepine prescribing and long-term opioid use. DESIGN/ SETTING: We performed a retrospective analysis of a commercial database containing claims for more than 75 million enrollees in the USA. PARTICIPANTS: Participants were adult patients newly diagnosed with LBP or LEP between 2008 and 2015 who did not have a red flag diagnosis, had not received an opioid prescription in the 6 months prior to diagnosis, and had 12 months of continuous enrollment after diagnosis. MAIN OUTCOMES AND MEASURES: Among patients receiving at least one opioid prescription within 12 months of diagnosis, we defined discrete patterns of benzodiazepine prescribing-continued use, new use, stopped use, and never use. We tested the association of these prescription patterns with long-term opioid use, defined as six or more fills within 12 months. RESULTS: We identified 2,497,653 opioid-naïve patients with newly diagnosed LBP or LEP. Between 2008 and 2015, 31.9% and 11.5% of these patients received opioid and benzodiazepine prescriptions, respectively, within 12 months of diagnosis. Rates of opioid prescription decreased from 34.8% in 2008 to 27.0% in 2015 (P < 0.001); however, prescribing of benzodiazepines only decreased from 11.6% in 2008 to 10.8% in 2015. Patients with continued or new benzodiazepine use consistently used more opioids than patients who never used or stopped using benzodiazepines during the study period (one-way ANOVA, P < 0.001). For patients with continued and new benzodiazepine use, the odds ratio of long-term opioid use compared with those never prescribed a benzodiazepine was 2.99 (95% CI, 2.89-3.08) and 2.68 (95% CI, 2.62-2.75), respectively. LIMITATIONS: This study used administrative claims analyses, which rely on accuracy and completeness of diagnostic, procedural, and prescription codes. CONCLUSION: Overall opioid prescribing for low back pain or lower extremity pain decreased substantially during the study period, indicating a shift in management within the medical community. Rates of benzodiazepine prescribing, however, remained at approximately 11%. Concurrent prescriptions of benzodiazepines and opioids after LBP or LEP diagnosis were associated with increased risk of long-term opioid use.
BACKGROUND: The morbidity and mortality associated with opioid and benzodiazepine co-prescription is a pressing national concern. Little is known about patterns of opioid and benzodiazepine use in patients with acute low back pain or lower extremity pain. OBJECTIVE: To characterize patterns of opioid and benzodiazepine prescribing among opioid-naïve, newly diagnosed low back pain (LBP) or lower extremity pain (LEP) patients and to investigate the relationship between benzodiazepine prescribing and long-term opioid use. DESIGN/ SETTING: We performed a retrospective analysis of a commercial database containing claims for more than 75 million enrollees in the USA. PARTICIPANTS: Participants were adult patients newly diagnosed with LBP or LEP between 2008 and 2015 who did not have a red flag diagnosis, had not received an opioid prescription in the 6 months prior to diagnosis, and had 12 months of continuous enrollment after diagnosis. MAIN OUTCOMES AND MEASURES: Among patients receiving at least one opioid prescription within 12 months of diagnosis, we defined discrete patterns of benzodiazepine prescribing-continued use, new use, stopped use, and never use. We tested the association of these prescription patterns with long-term opioid use, defined as six or more fills within 12 months. RESULTS: We identified 2,497,653 opioid-naïve patients with newly diagnosed LBP or LEP. Between 2008 and 2015, 31.9% and 11.5% of these patients received opioid and benzodiazepine prescriptions, respectively, within 12 months of diagnosis. Rates of opioid prescription decreased from 34.8% in 2008 to 27.0% in 2015 (P < 0.001); however, prescribing of benzodiazepines only decreased from 11.6% in 2008 to 10.8% in 2015. Patients with continued or new benzodiazepine use consistently used more opioids than patients who never used or stopped using benzodiazepines during the study period (one-way ANOVA, P < 0.001). For patients with continued and new benzodiazepine use, the odds ratio of long-term opioid use compared with those never prescribed a benzodiazepine was 2.99 (95% CI, 2.89-3.08) and 2.68 (95% CI, 2.62-2.75), respectively. LIMITATIONS: This study used administrative claims analyses, which rely on accuracy and completeness of diagnostic, procedural, and prescription codes. CONCLUSION: Overall opioid prescribing for low back pain or lower extremity pain decreased substantially during the study period, indicating a shift in management within the medical community. Rates of benzodiazepine prescribing, however, remained at approximately 11%. Concurrent prescriptions of benzodiazepines and opioids after LBP or LEP diagnosis were associated with increased risk of long-term opioid use.
Entities:
Keywords:
benzodiazepine; long-term opioid use; low back pain; opioid
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet Journal: J Gen Intern Med Date: 2016-08-02 Impact factor: 5.128
Authors: Laura S Gold; Ryan N Hansen; Andrew L Avins; Zoya Bauer; Bryan A Comstock; Richard A Deyo; Patrick J Heagerty; Sean D Rundell; Pradeep Suri; Judith A Turner; Jeffrey G Jarvik Journal: Clin J Pain Date: 2018-04 Impact factor: 3.442
Authors: Michael E Chernew; Lindsay M Sabik; Amitabh Chandra; Teresa B Gibson; Joseph P Newhouse Journal: Am J Manag Care Date: 2010-02 Impact factor: 2.229
Authors: Nancy E Morden; Jeffrey C Munson; Carrie H Colla; Jonathan S Skinner; Julie P W Bynum; Weiping Zhou; Ellen Meara Journal: Med Care Date: 2014-09 Impact factor: 2.983
Authors: Leonard J Paulozzi; Chao Zhou; Christopher M Jones; Likang Xu; Curtis S Florence Journal: Pharmacoepidemiol Drug Saf Date: 2016-02-10 Impact factor: 2.890
Authors: Jacob C Cogan; Rohit R Raghunathan; Melissa P Beauchemin; Melissa K Accordino; Elena B Elkin; Alexander Melamed; Jason D Wright; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2021-06-04 Impact factor: 4.872
Authors: Michael C Jin; Michael Jensen; Zeyi Zhou; Adrian Rodrigues; Alexander Ren; Maria Isabel Barros Guinle; Anand Veeravagu; Corinna C Zygourakis; Atman M Desai; John K Ratliff Journal: JAMA Netw Open Date: 2022-07-01
Authors: Michael C Jin; Jonathon J Parker; Michael Zhang; Zack A Medress; Casey H Halpern; Gordon Li; John K Ratliff; Gerald A Grant; Robert S Fisher; Stephen Skirboll Journal: J Neurosurg Date: 2021-05-14 Impact factor: 5.115
Authors: Stefania Di Gangi; Christophe Bagnoud; Giuseppe Pichierri; Thomas Rosemann; Andreas Plate Journal: J Pain Res Date: 2021-10-07 Impact factor: 3.133
Authors: Michael C Jin; Allen L Ho; Austin Y Feng; Zachary A Medress; Arjun V Pendharkar; Paymon Rezaii; John K Ratliff; Atman M Desai Journal: Neurospine Date: 2022-03-31